An analysis of biotechnology and non-biotechnology R&D capabilities in the Indian pharmaceutical industry

R and D Management

Volumn 27, Issue 2, 1997, Pages 177-180

  Visalakshi, S ^a   Sandhya, G D ^a  

^a National Institute of Science Technology and Development Studies India   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013093009     PISSN: 00336807     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-9310.00052     Document Type: Article

References (20)

1. Bower, D.J. (1993) How smaller companies are challenging the Pharmaceutical giants, in Blakely, E.J. and Willoughby, K.W. (eds) Biotech Review No. 1: The Management and Economic potential of Biotech., 120-128.
2. della Valle, F. and Gambardella, A. (1993) Biological revolution and strategies for innovation in the pharmaceutical companies. R&D Management, 23, no. 4, 287-302.
3. Dibner, M.D. (1985) Biotechnology in pharmaceuticals; the Japanese challenge. Science, 229. no. 20, 1231-1233.
4. Dibner, M.D. and Osterhaus, J.T. (1987) Biotechnology and pharmaceuticals merging together. Biopharm, Sep.: no. 60.
5. Dibner, M.D. and Bruce, N.G. (1987) Greening of biotechnology, the growth of the US biotechnology industry. Trends in Biotechnology, Oct.
6. Dibner, M.D., Greis, N. and Bailey Jr., J. (1990) Who's the competition in Biotech? Bio/Technology, 8(10), 920-922.
7. Drews, J. (1988) Future perspectives for the development of pharmaceutical and other health industries. Drugs Made in Germany, 31, no. 4, 109-113.
8. Dunhill, P. and Rudd, M. (1984) Biotechnology and British Industry. London, Biotechnology Directorate, UK Science and Engineering Research Council.
9. Ghosh, P.K. (1994) Personal communication.
10. Howells, J. (1990) The location and organisation of research and development: new horizons. Research Policy, 19, 133-146.
11. OECD (1984) Specialization and competitiveness in manufacturing industries of high medium and low R&D intensity; general trend. DSTI/SPR/84-49, Paris, mimeo.
12. OECD (1989) Biotechnology: Economic and Wider Impact, Paris, Organization for Economic Cooperation and Development.
13. Reis-Arndt, E. (1987) A quarter of a century of pharmaceutical research: new drug entities, 1961-85. Drugs Made in Germany, 30 no. 3, 105-112.
14. Rothwell, R. and Dodgson, M. (1991) External linkages and innovation in small and medium sized enterprises. R&D Management, 21, no. 2, 125-138.
15. Sapienza, A. (1989) Technology transfer of an assessment of the major institutional vehicle for diffusion of US biotechnology. Technovation, 9, 463-478.
16. Truscheit, E. (1986) the impact of biotechnology on the pharmaceutical industry. Drugs Made in Germany, 29, no. 3, 126-134.
17. UNIDO (1975) The Steps Involved in Establishing a Pharmaceutical Industry in Developing Countries. Vienna, UNIDO.
18. Visalakshi, S. (1995) R&D and commercialisation status of hybridoma technology in India: an international comparison. Science and Public Policy, 22(4), 231-238.
19. Vordervijlbecke, U. (1986) Perspectives of the pharmaceutical industry: problems, tasks and opportunities. Drugs Made in Germany, 29, no. 4, 171-178.
20. Whittaker, E. and Bower, D.J. (1994) A shift to external alliances for product development in the pharmaceutical industry. R&D Management, 24, no. 3, 249-261.